Peptide Inhibiting p68-Calmodulin Binding to Block Cancer Metastasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer metastasis remains a significant challenge in cancer treatment, with existing methods failing to effectively inhibit the migration of cancer cells, leading to high mortality rates due to the spread of cancer beyond its original tissue.
Innovation Solution
The use of peptides or antibodies that selectively inhibit the binding of p68 RNA helicase to calmodulin (CaM) in cancer cells, specifically targeting the IQ motif of p68, to disrupt the interaction essential for cell migration and metastasis, combined with cell-penetrating sequences for effective penetration into cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatment methods are used, then tumor growth can be controlled, but cancer cell metastasis is not effectively inhibited
Solution Approach 1:
The patent extracts and targets the specific p68-CaM interaction mechanism that drives metastasis, separating this pathological function from normal cellular processes. By designing peptides that specifically bind to the p68 IQ motif, the invention isolates and inhibits only the metastasis-promoting interaction while leaving other cellular functions intact.
Solution Approach 2:
The patent introduces peptide intermediaries that bind to the p68 IQ motif and prevent its interaction with calmodulin. These peptide mediators act as molecular blockers, interfering with the p68-CaM complex formation that is essential for metastasis, thereby preventing the harmful effect without disrupting overall cellular function.
2Reliability
If broad-spectrum anti-cancer agents are administered, then tumor growth is inhibited, but normal cell function is also affected
Solution Approach 1:
The patent applies local quality by designing peptides with specific sequences (e.g., FVSAGIQTSFRTGNPTGTYQ) that target only the p68 IQ motif structure. This specificity ensures that the inhibitory action is localized to the metastasis pathway involving p68-CaM interaction, while other cellular processes that do not involve this specific interaction remain unaffected.
Solution Approach 2:
The patent changes the binding parameters by introducing cell-penetrating sequences (such as TAT sequence) to the therapeutic peptides, enabling them to cross cell membranes and reach intracellular targets. This parameter modification allows the peptides to access and inhibit p68-CaM interaction inside cancer cells without affecting extracellular normal cells.
3Strength
If peptide size is increased to improve binding affinity, then binding strength to p68 increases, but cell penetration ability decreases
Solution Approach 1:
The patent segments the peptide into functional domains: a binding domain (containing the IQ motif sequence for p68 recognition) and a cell-penetrating domain (such as TAT sequence). This segmentation allows each domain to optimize its function - the binding domain maintains high affinity while the penetrating domain enables cellular uptake, resolving the size-affinity-penetration trade-off.
Data Source
AI summary
Compositions and methods for inhibiting cancer cell metastasis and inflammation are disclosed. The methods generally involve administering to a subject a composition containing an agent that selectively inhibits the binding of p68 RNA helicase to calmodulin (CaM) in the cells.